Baidu
map

J Am Acad Dermatol:化脓性汗腺炎与亚临床动脉粥样硬化

2016-08-06 Mechront 译 MedSci原创

目的:慢性炎症性疾病与亚临床动脉粥样硬化的患病率增加有关。化脓性汗腺炎(HS)是一种慢性炎症性疾病包括皮肤擦烂。我们试图探讨HS和亚临床动脉粥样硬化之间的潜在关联。方法:这项研究包括68例患者和136名年龄和性别匹配的健康对照组。排除有心血管事件史、糖尿病、慢性肾脏病或其他炎性疾病的患者。通过颈动脉超声测量颈动脉内中膜厚度和颈动脉斑块。调整了年龄、性别和传统的心血管危险因素。结果:患者比对照组有更

目的:慢性炎症性疾病与亚临床动脉粥样硬化的患病率增加有关。化脓性汗腺炎(HS)是一种慢性炎症性疾病包括皮肤擦烂。我们试图探讨HS和亚临床动脉粥样硬化之间的潜在关联。

方法:这项研究包括68例患者和136名年龄和性别匹配的健康对照组。排除有心血管事件史、糖尿病、慢性肾脏病或其他炎性疾病的患者。通过颈动脉超声测量颈动脉内中膜厚度和颈动脉斑块。调整了年龄、性别和传统的心血管危险因素。

结果:患者比对照组有更大的颈动脉内膜中层厚度值(0.615 ± 0.097 vs 0.578 ± 0.098 mm; P = .012)。患者比对照组的拥有颈动脉斑块的比例也更高(30.9% vs 22.1%)。在调整了年龄、性别和传统的心血管危险因素的多变量回归模型中,HS与颈动脉粥样硬化斑块的存在显著相关(OR=2.99, 95% CI 1.26-7.13; P = .013)。无法评估因果关系是本研究的限制之一。

结论:这些结果表明,HS患者的亚临床动脉粥样硬化频率增加。因此,HS可能是潜在增加心血管风险的疾病。

原始出处:


González-López MA.et al.Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS).J Am Acad Dermatol. 2016 Aug;75(2):329-35. doi: 10.1016/j.jaad.2016.03.025.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1748161, encodeId=639a1e4816172, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Fri Mar 10 01:16:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651832, encodeId=538816518322d, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Jun 23 03:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944415, encodeId=f6911944415c9, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Apr 11 15:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735802, encodeId=a6931e3580219, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Tue Apr 11 01:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122052, encodeId=ac941220525e, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:10:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112458, encodeId=6aaa1124582c, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 16:17:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1748161, encodeId=639a1e4816172, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Fri Mar 10 01:16:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651832, encodeId=538816518322d, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Jun 23 03:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944415, encodeId=f6911944415c9, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Apr 11 15:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735802, encodeId=a6931e3580219, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Tue Apr 11 01:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122052, encodeId=ac941220525e, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:10:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112458, encodeId=6aaa1124582c, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 16:17:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2017-06-23 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1748161, encodeId=639a1e4816172, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Fri Mar 10 01:16:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651832, encodeId=538816518322d, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Jun 23 03:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944415, encodeId=f6911944415c9, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Apr 11 15:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735802, encodeId=a6931e3580219, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Tue Apr 11 01:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122052, encodeId=ac941220525e, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:10:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112458, encodeId=6aaa1124582c, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 16:17:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1748161, encodeId=639a1e4816172, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Fri Mar 10 01:16:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651832, encodeId=538816518322d, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Jun 23 03:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944415, encodeId=f6911944415c9, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Apr 11 15:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735802, encodeId=a6931e3580219, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Tue Apr 11 01:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122052, encodeId=ac941220525e, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:10:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112458, encodeId=6aaa1124582c, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 16:17:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1748161, encodeId=639a1e4816172, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Fri Mar 10 01:16:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651832, encodeId=538816518322d, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Jun 23 03:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944415, encodeId=f6911944415c9, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Apr 11 15:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735802, encodeId=a6931e3580219, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Tue Apr 11 01:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122052, encodeId=ac941220525e, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:10:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112458, encodeId=6aaa1124582c, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 16:17:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-11 1e10c84am36(暂无匿称)

    己拜读,受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1748161, encodeId=639a1e4816172, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Fri Mar 10 01:16:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651832, encodeId=538816518322d, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Jun 23 03:16:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944415, encodeId=f6911944415c9, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Apr 11 15:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735802, encodeId=a6931e3580219, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Tue Apr 11 01:16:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122052, encodeId=ac941220525e, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:10:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112458, encodeId=6aaa1124582c, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 16:17:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 李东泽

    很好,不错,以后会多学习

    0

相关资讯

JAMA:老年男性服用睾酮对亚临床动脉粥样硬化进展的影响

    睾酮在老年男性中的应用正在增加,但其对动脉粥样硬化进展的长期影响尚不清楚。该研究的目的是确定睾酮的使用对于有着低或低-正常睾丸激素水平老年男性亚临床动脉粥样硬化患者进展的影响。    睾酮对老年男性动脉粥样硬化进展的影响研究(TEAAM)是一个安慰剂对照,双盲,平行组随机试验,涉及308名60岁或以上的低或低睾酮水平正常(100-400ng/dL;游

亚临床动脉粥样硬化影像学评估研究进展

美国经导管心血管治疗学术会议(TCT2015)专题报道 作者:上海交通大学医学院附属仁济医院 沈玲红 10月12日TCT午间热点话题围绕易损斑块的临床检测和治疗进展展开。迈赫兰(Roxana Mehran)教授重点介绍了动脉粥样硬化性心血管疾病一级预防风险评估的最新研究BioImage Study和PESA Study。 BioImage Study旨在探讨各种无创检

Baidu
map
Baidu
map
Baidu
map